BioMarin Pharmaceutical Inc is turning to the theater to establish its name with hemophilia patients, long before its experimental cure for the bleeding disorder could reach the market.
Search
Recent Posts
- Shopify, BlackBerry develop COVID-19 app; Canada to roll out voluntary tests
- Ahead of Trump rally in Oklahoma, coronavirus cases surge in several states
- Amazon to use AI tech in its warehouses to enforce social distancing
- China's new virus outbreak needs further testing after 'hypothesis' on cause: WHO
- Record spikes in new coronavirus cases, hospitalizations sweep parts of U.S.
- U.S. CDC reports 2,038,344 coronavirus cases
- Coronavirus hitting the Americas hardest says World Health Organization
- Only French victims of faulty breast implant may claim damages, EU court says
- WHO hopes to work with U.S. on Ebola despite Trump criticism over COVID-19
- Germany to extend virus-related travel ban for non-European countries
- France's new confirmed cases of coronavirus slow down
- U.S. coronavirus deaths top 110,000 as cases approach 2 million: Reuters tally
- Indonesia reports biggest daily rise in coronavirus infections
- Factbox: What the WHO recommends on face masks
- Vaccines group raises $8.8 billion for immunisation plans for poor countries
- Sanofi to run consultations over restart of hydroxychloroquine trials
- 'A great sadness': Bolivia strains under COVID-19 as cases top 10,000
- UK COVID-19 confirmed death toll rises to 39,045
- Thailand's parliament approves $58 billion economic package to ease virus impact
- Drugs standards group nixes plan to kick pharma's crab blood habit